VSTM Key Stats
- Verastem to Present at the 2013 ASCO Annual Meeting Business Wire May 23
- Verastem to Present at Upcoming Conferences Business Wire May 21
- VERASTEM, INC. Financials May 17
- Friday 5/17 Insider Buying Report: WFR, VSTM May 17
- Verastem Hires a CFO May 15
- CFO Moves: Cigna, Edwards Lifesciences, Verastem May 14
- Jack Green Named Verastem CFO Benzinga May 14
- Verastem appoints Jack Green as CFO May 14
- Jack Green Joins Verastem as Chief Financial Officer Business Wire May 14
- VERASTEM, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Su... May 14
VSTM Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Verastem is down 3.47% over the last year vs S&P 500 Total Return up 27.96%, AVEO Pharmaceuticals down 77.55%, and ARCA biopharma down 0.31%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for VSTM
Pro Report PDF for VSTM
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download VSTM Pro Report PDF
Pro Strategies Featuring VSTM
Did Verastem make it into our Pro Portfolio Strategies?